ZBTB18
protein-codingzinc finger and BTB domain containing 18, the group of Zinc fingers C2H2-type|BTB domain containing
Gene summary
This gene encodes a C2H2-type zinc finger protein which acts a transcriptional repressor of genes involved in neuronal development. The encoded protein recognizes a specific sequence motif and recruits components of chromatin to target genes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]
- ZNF238
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~8.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0012869
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0100038
Submitter: ClinGen
*ZBTB18* encodes a transcriptional repressor involved in various developmental processes, including brain development. *ZBTB18* was first reported in relation to autosomal dominant complex neurodevelopmental disorder in 2014 (de Munnik et al., PMID: 24193349). Phenotypic features include global developmental delay particularly affecting speech, intellectual disability, hypotonia, microcephaly, short stature, dysmorphic features, epilepsy, corpus callosum abnormalities, congenital anomalies, and behavioral abnormalities. Eleven variants (frameshift, nonsense, and missense) that have been reported in 12 probands in 7 publications (PMIDs: 23020937, 24193349, 26740508, 27598823, 28135719, 29573576, 31238879) are included in this curation. All variants occurred *de novo*. More evidence is available in the literature but the maximum score for genetic evidence (12 points) has been reached. Nonsense and frameshift variants lead to a premature termination codon in the last (second) exon and are not expected to result in nonsense-mediated decay. The majority of disease-associated missense variants are found within the C-terminal zinc finger DNA-binding region, which is essential for transcriptional regulation. The mechanism of pathogenicity for truncating variants appears to be loss of function. The mechanism of missense variants is not well elucidated but *in vitro* functional studies of two missense variants demonstrated impaired transcriptional repression for p.Asn461Ser and potentiation of gene transcription for p.Arg495Gly (PMID: 31112317). This gene-disease relationship is also supported by experimental evidence. *Zbtb18* heterozygous knockout mice exhibit impaired learning and memory, glutamatergic synaptic dysfunction, and corpus callosum defects (PMID: 36721027). In summary, there is definitive evidence supporting the relationship between *ZBTB18* and autosomal dominant complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on December 14, 2023. It was reevaluated on May 22, 2026 (SOP Version 12). As a result of this reevaluation, the classification did not change.
Inheritance Pattern: AD
Disease ID:MONDO:0012869
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0012869
Submitter: Illumina
Inheritance Pattern: AD
Disease ID:MONDO:0012869
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ZBTB18 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_205768.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 87 | 3 | 91 | ||
| missense | 2 | 32 | 154 | 19 | 13 | 220 |
| nonsense | 13 | 4 | 2 | 19 | ||
| start loss | 0 | |||||
| frameshift | 22 | 11 | 2 | 35 | ||
| splice donor/acceptor (+/-2bp) | 2 | 2 | ||||
| Total | 37 | 47 | 161 | 106 | 16 | 367 |
Highest pathogenic variant AF is 0.0000041046296
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_991331.1 | 2 | MANE Select | |
| Ensembl | ENSP00000351539.4 | 2 | MANE Select | |
| RefSeq | NP_001265125.1 | 1 | Standard | |
| RefSeq | NP_001408495.1 | 3 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- negative regulation of transcription by RNA polymerase II
- cellular response to DNA damage stimulus
- skeletal muscle tissue development
- negative regulation of transcription, DNA-templated
- positive regulation of transcription by RNA polymerase II
Molecular Function
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA binding
- DNA-binding transcription factor activity
- transcription coactivator activity
- protein binding
Cellular Component
- nuclear chromosome
- nucleus
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000358704
- Coding exons
- 2
- Length
- 6194
- Individuals with no LoFs
- 0
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 0
- Defined
- 0
- p
- 0.00
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.43 | 150 | 324 | 0.463 | 0.0000194 | 3542 |
| Missense (PolyPhen) | 27 | 127.87 | 0.21116 | 1382 | ||
| Synonymous | -0.314 | 146 | 141 | 1.03 | 0.0000102 | 1012 |
| Loss of Function | 3.79 | 0 | 16.7 | 0.00 | 9.79e-7 | 203 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Transcriptional repressor that plays a role in various developmental processes such as myogenesis and brain development. Plays a key role in myogenesis by directly repressing the expression of ID2 and ID3, 2 inhibitors of skeletal myogenesis. Also involved in controlling cell division of progenitor cells and regulating the survival of postmitotic cortical neurons. Specifically binds the consensus DNA sequence 5'- [AC]ACATCTG[GT][AC]-3' which contains the E box core, and acts by recruiting chromatin remodeling multiprotein complexes. May also play a role in the organization of chromosomes in the nucleus. {ECO:0000269|PubMed:9756912}.;
Recessive Scores
- pRec
- 0.121
Intolerance Scores
- RVIS EVS
- -0.78
- RVIS percentile EVS
- 12.77
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |